-
Taxonomy & unit
-
us-gaap: USD/shares
-
Description
-
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
-
Summary
-
Bionik Laboratories Corp. quarterly/annual Earnings Per Share, Diluted history and growth rate from Q3 2014 to Q1 2023.
- Bionik Laboratories Corp. Earnings Per Share, Diluted for the quarter ending March 31, 2023 was -0.2 USD/shares, a 33.3% increase year-over-year.
- Bionik Laboratories Corp. Earnings Per Share, Diluted for the twelve months ending March 31, 2023 was -0.72 USD/shares, a 59.6% increase year-over-year.
- Bionik Laboratories Corp. annual Earnings Per Share, Diluted for 2022 was -0.72 USD/shares, a 59.6% increase from 2021.
- Bionik Laboratories Corp. annual Earnings Per Share, Diluted for 2021 was -1.78 USD/shares, a 33.1% increase from 2020.
- Bionik Laboratories Corp. annual Earnings Per Share, Diluted for 2020 was -2.66 USD/shares.
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Quarterly (USD/shares)
Earnings Per Share, Diluted, YoY Quarterly Growth (%)